RecruitingNot ApplicableNCT05156385

Sexual Dysfunction in Hypertensive Women

Sexual Dysfunction in Hypertensive Women According to Drug Adherence: Multicenter Cross-sectional Study


Sponsor

University Hospital, Toulouse

Enrollment

348 participants

Start Date

Jun 27, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

Several studies describe the existence of an association between sexual dysfunction and high blood pressure (hypertension), most often characterized by a decrease in the number of orgasms and the existence of dyspareunia. Hypertension is a contributing factor, and nonadherence to medication could amplify it. There are several ways to assess adherence to treatment: the use of declarative questionnaires, a method not without criticism because it is subject to the subjectivity of the declaration by the patient; and drug dosages, a standard technique, although insufficiently disseminated due to the high cost and greater weight of the survey protocols. Drug non-compliance is multifactorial. In addition, it has been shown that having undesirable drug effects and / or being afraid of developing them is one of the major causes of non-compliance with antihypertensive treatments. The investigators hypothesize that DS is significantly more common among hypertensive women treated with non-observers compared to hypertensive women treated with observers. The main objective is to compare the prevalence of sexual dysfunction between a group of hypertensive women treated as observers and a group of hypertensive women treated as non-observers.


Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria4

  • Women over 18,
  • Hospitalized or received in consultation for the management of hypertension treated in one of the hypertension and therapeutic, nephrology or cardiology departments participating in the study, with confirmed hypertension, treated with the following dosable antihypertensive agent(s): diltiazem, verapamil, acebutolol, atenolol, nébivolol, bisoprolol, metoprolol, propranolol, amiloride, furosemide, hydrochlorothiazide, indapamide, spironolactone, spironolactone, Lorsartan, Irbesartan, Ramipril, Perindopril, Amlodipine,
  • Having signed the informed consent form.
  • Beneficiary or affiliated to a French Social insurance

Exclusion Criteria3

  • Patients with bariatric surgery,
  • Patients under guardianship/trusteeship/protection of justice,
  • Patients with diagnosed and treated psychosis or depression, - Pregnant or nursing women.

Interventions

BIOLOGICALBlood sample for the determination of antihypertensives or their metabolites.

15 ml of Blood sample for the determination of antihypertensives or their metabolites

BEHAVIORALQuestionnaire on sexual activity

Questionnaire on sexual activity in women

BEHAVIORALScale on hospital anxiety and depression

Scale on hospital anxiety and depression to detect anxious and depressive symptoms (14 questions)

BEHAVIORALMorisky Questionaire

anti-hypertensive medication compliance questionnaire


Locations(1)

LAZARO Delphine

Toulouse, CHU de Toulouse, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05156385


Related Trials